This week, we will discuss the role of ApoE in determining the subtypes of C3 Glomerulopathy.
This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
Third instalment of our NephJC summary tweetorials - catch it at the link to learn more about the trade-offs in timing when best to start dialysis in progressive CKD.
Welcome to #TenTweetNephJC
— Nephrology Jrnl Club (@NephJC) February 16, 2022
✳️ 10 tweets to catch-up on the most recent #NephJC ✳️
This week - when is the ideal time to start dialysis in progressive chronic kidney disease?
Later starts lower the burden on patients & use of healthcare resources, but what’s the trade-off? pic.twitter.com/CG2YavjzEQ
Created in a time crunch, the visual abstract for this week’s study from Elena Cervantes:
